Aktive Positionen von Yihai Cao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Direktor/Vorstandsmitglied | 01.01.2006 | - |
| Gründer | 01.01.2006 | - |
Karriereverlauf von Yihai Cao
Ehemalige bekannte Positionen von Yihai Cao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - | - |
Ausbildung von Yihai Cao
| University of Copenhagen | Doctorate Degree |
Statistik
International
| Schweden | 3 |
| Dänemark | 2 |
Operativ
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
